chartexchange

Palvella Therapeutics Inc (PVLA) (Q3 2026) Earnings Call Highlights: FDA Priority Review, $236. ...

GuruFocus | Nov 5, 2026 6:16 PM EST

Palvella Therapeutics Inc (PVLA) advances its Qtorin rapamycin NDA toward a February 2027 PDUFA date while funding a standalone U.S. launch and a deep pipeline of first-in-disease programs. Related Stocks: PVLA ,

Read original article